Jansen Pharmaceuticals has requested that we let our blog readers know about an upcoming educational webinar they are sponsoring on Tuesday, 9/18/18, 7 p.m. ET. The webinar will be discussing their newly approved treatment, apalutamide (Erleada) which is approved by the FDA for men with castrate resistant, non-metastatic prostate cancer, sometimes referred to as M0 (M-zero) disease.
Home healthcare can include many different services that are delivered to you in your home. Medicare will cover some of your home healthcare needs, however you will need to meet certain stringent conditions to be eligible for the coverage.
A study determined that there is a psychological morbidity rate of over 80% experienced by caregivers of patients with terminal cancer.
Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
Through the work of Huggins et al.  in 1941, it was shown that metastatic prostate cancer responds positively to an orchiectomy (surgical castration). We now know that there isn’t any other therapy which produces a more reliable regression of both distant and local disease than androgen withdrawal (ADT).
Continuous long-term ADT significantly reduces the sensitivity and visibility of castration-sensitive prostate cancer on PSMA PET/CT scans.
In a recent study of 258 men with otherwise untreatable castrate resistant prostate cancer the immunotherapy drug Pembrolizumab showed that it was able to control the disease having a positive response lasting six months or more in 11 percent of men, with two men showing a complete response.
The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted. The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies.
Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.
When this happens, the question that comes is what should be the next treatment? Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).
The FDA now will accept Metastasis-Free Survival (MFS) as a clinical trial endpoint for hormone sensitive cancer.
Update 1- The Metastatic Prostate Cancer Project files its first report to its participants.
An estimated one-fifth or more men with metastatic castration-resistant prostate cancer (mCRPC) harbor defects in genes involved in their DNA repair pathway (e.g., BRCA2, BRCA1, and others).
Initially being diagnosed with metastatic, or advanced prostate cancer is not great. Metastatic prostate cancer is not curable and will be terminal if you don’t die from another cause.
We now have a number of what we consider second-line treatments for prostate cancer, drugs like Zytiga, Xtandi and Taxotere (chemotherapy).
We are beginning to recognize the value of the early use of these second line drugs along with first line ADT for men who are initially diagnosed with metastatic prostate cancer.
Developing or being diagnosed with Prostate Cancer and having bone metastases is not good news.
Metformin is an inexpensive drug that might be able to be used with men with advanced prostate cancer who are on hormone therapy (ADT).
Since the approvals for the early use of docetaxel chemotherapy (Taxotere) and the early use of abiraterone acetate (Zytiga) there is no clear evidence demonstrating which of these two agents should be used for men with hormone sensitive, newly diagnosed, aggressive prostate cancer.
Why you should take Provenge (sipuleucel-T) simply using evidence based logic.
A newly identified subtype of prostate cancer characterized by the loss of the gene CDK12 was found to be more common in men with metastatic prostate cancer compared to non-metastatic disease. What makes this discovery very important is that prostate cancer with the inactivation or loss of the CDK12 gene seems to be responsive to checkpoint inhibitors.
Investigators have reported that based on a multicenter, international phase II study the currently approved dose of Ra-223 appears to be optimal.
In a surprising analysis it was determined that the overall survival (OS) between African American and Caucasian men with metastatic castration-resistant prostate cancer (mCRPC) favors African Americans!